TB

Tom Burt

Head of Life Sciences at Triton Partners

Greater London, England

Overview 

Tom Burt is currently the Head of Life Sciences at Triton Partners in Greater London, England. With a background in investment banking and private equity, Tom has successfully invested in companies like Synthace (Series C) and Sphere Fluidics (Series Unknown), showcasing his expertise in the biotechnology and healthcare sectors. Tom's career highlights include serving as a Partner at Sofinnova Partners and working as a Senior Research Analyst at Peel Hunt, demonstrating his strong track record in evaluating and investing in emerging technologies and life sciences companies.

Work Experience 

TP

Triton Partners

  • Head of Life Sciences

    2023 - Current

SP

Sofinnova Partners

  • Partner

    2017 - 2023

    - Investments made into Limflow, MaxCyte, Redx Pharma, Sphere Fluidics & Synthace - Board member: Redx Pharma, SphereFluidics [Interim Chair] & Synthace [Interim Chair]

PH

Peel Hunt

  • Senior Research Analyst [Healthcare & Life Sciences]

    2015 - 2017

    Stockbroking and advisory firm serving the UK small & mid-cap market Initiation/ Coverage included: Clinigen, PureTech, Electrical Geo, Abcam, ConvaTec

ARES LIFE SCIENCES LLP

  • Investment Director

    2013 - 2015

    Late-venture/growth equity fund investing in EU Healthcare & Life sciences with c.EUR2bn AUM Responsibilities included: - Transaction Management - Investment Oversight/ Portfolio Assistance - Valuation Analysis - Commercial/Technical assessment of new investment opportunities Portfolio: Esaote/ Euromedic/ Santhera/ Stallergenes Examples of Completed Transactions include: Euromedic: concurrent sell-side auction (c. EUR 1bn) and minority s/h acquisition (09/2014). Re-financing (02/2013) and divestment of Czech labs (10/2013) Esaote: minority s/h acquisition (07/2014). Re-financing (07/2015)

NA

Novo A/S

  • Associate, Novo Growth Equity

    2010 - 2013

    Late-venture/growth equity division of Novo Holdings investing US$200m p.a in EU/US Healthcare & Life science companies Responsibilities included: - Valuation Analysis - Commercial Assessment - Due Diligence - Investment Oversight/ Portfolio Assistance / Business Development Examples of Completed Transactions include: - Archimedes Pharma Ltd: GBP 65m Series D Investment/ Warburg Pincus stake acquisition - Orexo AB: SEK 150m Secondary purchase/ SEK 111m Convertible loan/ SEK 250m Rights Iss. - Aerocrine AB:SEK 112m Directed Issue/ SEK 112m Convertible loan - Novo A/S DKK 4.1bn Secondary purchase in Chr.Hansen A/S/ US$700m Acquisition of Xellia Pharmaceuticals

PJ

Piper Jaffray

  • Associate, Healthcare Investment Banking

    2006 - 2010

    European Healthcare/Life Science Investment Banking (M&A/ ECM/ DCM) Examples of Completed Transactions include: - ECM: Santhera CHF 100m IPO / TiGenix €46m IPO / Basilea CHF 324m Follow-on/ NicOx €129m Follow-on/ SkyePharma GBP 21.0m Placing - M&A: Biocompatibles- BrachySciences/ Parexel-ClinPhone/ Protherics-Macromed/ Lonza-Amaxa/ ProStrakan-Cellegy Assets/ BTG-Protherics

Piper Jaffray Merchant Banking (PJMB) is a part of the asset management business of Piper Jaffray Companies

piperjaffray.com
G

GlaxoSmithKline

  • Research Engineer

    2001 - 2005

    DNA vaccine production/ scale-up

Education 

Investments 

Synthace

Series C

Total funding: $75M

Sphere Fluidics

Series Unknown

Total funding: $41M

Articles About Tom

Relevant Websites